Clinical Trial Update: Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intramuscular PLX PAD for critical limb ischemia with minor tissue loss in patients unsuitable for revascularization, assessing efficac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia

Drugs mentioned

• PLX PAD

Snippet

Sponsor: Pluristem Ltd. | Conditions: Critical Limb Ischemia (CLI) | Phase 3 | Status: COMPLETED